<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30290608</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>40</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging.</ArticleTitle>            <Pagination>                <MedlinePgn>e12518</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012518</ELocationID>            <Abstract>                <AbstractText>The everolimus-exemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. The objective of the study was to determine the frequency of everolimus lung side effects and investigate their imaging characteristics on positron emission tomography with 18F-fluoro-deoxy-glucose combined with computerized tomography (F-FDG PET/CT).Our single-center retrospective descriptive study systematically included all patients with metastatic breast cancer treated by this combination (n = 29 representing 57 F-FDG PET/CT). Number of segments involved was quantified. Maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), metabolic target volume (MTV), and total lesion glycolysis (TLG) were measured. Severe pneumopathy was studied by subgroup analysis.Pleuroparenchymal anomalies rate detected on F-FDG PET/CT was 62%. Alveolar-interstitial lesions were mainly observed (89%) and affected 2.8 segments (0.5-11.5) with a median of 2 segments. S7 and S10 were the most involved segments with SUVmax 3.9 (1.3-8.8) and SUVmean 2.2 (0.7-4.9). Statistically significant difference (P = .02) was found with number of segment involved to characterize severe pneumopathy (average of 6.3 segments [2.5-11.5] vs 1.9 segments [0.5-8] for interstitial lung disease) but not with SUVmax, SUVmean, MTV, TLG (P = .14, 0.22, 0.22, and 0.17, respectively).The F-FDG PET/CT could highlight pulmonary everolimus side effects, with a typical imaging pattern: alveolar-interstitial opacities associated with moderate uptake, more or less extensive, mainly affecting the lower lobes. Rarely, a pseudotumoral aspect may be detected, corresponding to a pitfall. MTV or TLG showed a tendency to differentiate severe pneumopathy vs interstitial lung disease but no statistically significant differences was observed contrarily to the number of segments involved. Further studies are necessary to determine if the F-FDG PET/CT could early predict adverse effects of mTOR inhibitors.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Dejust</LastName>                    <ForeName>Sebastien</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morland</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratory of Biophysics, University of Reims.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bruna-Muraille</LastName>                    <ForeName>Claire</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eymard</LastName>                    <ForeName>Jean-Christophe</ForeName>                    <Initials>JC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yazbek</LastName>                    <ForeName>Gabriel</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Savoye</LastName>                    <ForeName>Aude-Marie</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Papathanassiou</LastName>                    <ForeName>Dimitri</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratory of Biophysics, University of Reims.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Research Center in Information and Communication Sciences and Technologies, EA 3804, University of Reims, Reims, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0Z5B2CJX4D</RegistryNumber>                <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>9HW64Q8G6G</RegistryNumber>                <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.1.1</RegistryNumber>                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>NY22HMQ4BX</RegistryNumber>                <NameOfSubstance UI="C056516">exemestane</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2016 May 13;6:25615</RefSource>                <PMID Version="1">27174543</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Ther. 2013 Oct;30(10):870-84</RefSource>                <PMID Version="1">24158787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2015 Dec 07;8:3629-38</RefSource>                <PMID Version="1">26675495</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2015;11(12):1809-28</RefSource>                <PMID Version="1">26075448</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2013 Apr;54(4):647-58</RefSource>                <PMID Version="1">23359660</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Ther. 2016 Apr;38(4):905-17</RefSource>                <PMID Version="1">26947172</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2015 Sep;20(9):1077-83</RefSource>                <PMID Version="1">26205737</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2013 Aug;140(3):453-62</RefSource>                <PMID Version="1">23907751</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2012 Jul;48(10):1519-24</RefSource>                <PMID Version="1">22483544</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2014 May;15(6):580-91</RefSource>                <PMID Version="1">24742739</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2010 Sep 15;116(18):4256-65</RefSource>                <PMID Version="1">20549832</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2009 Sep;9(9):631-43</RefSource>                <PMID Version="1">19701242</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Med Res Opin. 2016;32(2):385-94</RefSource>                <PMID Version="1">26651842</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Apr 1;22(7):1699-712</RefSource>                <PMID Version="1">26546619</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2014 Aug 15;135(4):1007</RefSource>                <PMID Version="1">24415627</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2016 Feb;16(1):18-22</RefSource>                <PMID Version="1">26507507</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2013 Dec;13(6):421-432.e8</RefSource>                <PMID Version="1">24267730</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transpl Int. 2014 May;27(5):428-36</RefSource>                <PMID Version="1">24484452</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Drug Saf. 2016 Aug;15(8):1075-85</RefSource>                <PMID Version="1">27210004</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Clin Pharmacol. 2016 Nov;82(5):1189-1212</RefSource>                <PMID Version="1">27059645</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1997 Dec 15;80(12 Suppl):2505-9</RefSource>                <PMID Version="1">9406703</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2016 May 15;138(10):2312-21</RefSource>                <PMID Version="1">26452336</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Dec;25(12):2357-62</RefSource>                <PMID Version="1">25231953</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology. 2015;89(6):319-31</RefSource>                <PMID Version="1">26457979</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancers (Basel). 2014 Sep 29;6(4):1821-89</RefSource>                <PMID Version="1">25268160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Am Thorac Soc. 2013 Dec;10(6):727-9</RefSource>                <PMID Version="1">24364783</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Oncol. 2012 Sep;51(7):873-9</RefSource>                <PMID Version="1">22909392</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Respir Crit Care Med. 2010 Aug 1;182(3):396-403</RefSource>                <PMID Version="1">20194812</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000730" MajorTopicYN="N">Androstadienes</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30290608</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012518</ArticleId>            <ArticleId IdType="pii">00005792-201810050-00022</ArticleId>            <ArticleId IdType="pmc">PMC6200531</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>